A 43-year-old woman self-administered 18 mg of liraglutide over 3 days (10x the recommended dose) for weight loss, developing severe diabetic ketoacidosis with pH 6.9 that required emergency hemodialysis to survive.
pH 6.9 — life-threatening acidosisMassive liraglutide overdose (18 mg over 3 days, 10× dose) caused the most severe documented DKA from GLP-1 agonist misuse, requiring salvage hemodialysis
What the researchers found
A cumulative liraglutide dose of 18 mg over 3 days (10x the recommended maximum of 1.8 mg/day) induced severe DKA with pH 6.9, markedly elevated β-hydroxybutyrate, and hyperkalemia. Conventional DKA management (IV fluids, insulin, electrolyte correction) failed to correct the profound acidosis. Salvage hemodialysis was required and rapidly stabilized metabolic parameters. This represents one of the most severe documented cases of GLP-1 receptor agonist overdose-induced DKA.
Why it matters
As GLP-1 drugs gain popularity for weight loss, the risk of misuse — patients self-dosing beyond prescriptions to accelerate results — is a growing concern. This case demonstrates that GLP-1 overdose can cause life-threatening metabolic emergencies even in type 2 diabetes patients, who are typically at low risk for DKA. Clinicians prescribing these drugs need to explicitly counsel patients about the dangers of dose escalation and the risk of DKA.
How the study worked
Single case report of a 43-year-old female with type 2 diabetes mellitus who self-administered a massive liraglutide overdose. Clinical course, laboratory values, treatment approach, and outcome are documented.
What this study cannot tell us
This is a single case report and cannot establish the frequency or predictability of DKA from liraglutide overdose. The patient's underlying diabetes and metabolic status may have contributed to her vulnerability. The mechanism by which liraglutide overdose triggers DKA in a type 2 diabetes patient (typically protected from DKA by residual insulin secretion) is not fully explained. Case reports cannot determine dose-response relationships for adverse events.
How to read the evidence
This is a single case report — the lowest level of clinical evidence. However, it documents a rare, life-threatening adverse event from GLP-1 drug overdose that has important safety implications given the widespread use of these medications.
When this study was published
Published in 2026, this case report is highly relevant given the current global surge in GLP-1 drug use for weight loss and emerging reports of misuse and diversion.
The bigger picture
GLP-1 drug misuse is an emerging safety concern as semaglutide, liraglutide, and tirzepatide become among the most-prescribed medications worldwide. With immense public demand for weight loss and limited medication supply, some patients take matters into their own hands — increasing doses, sharing prescriptions, or obtaining medications from unregulated sources. This case report serves as a warning that these peptide drugs have a serious side effect ceiling and that more is not better.
Questions still open
- At what threshold dose does liraglutide overdose become life-threatening — is there a clear dose-toxicity relationship?
- Should GLP-1 drug prescriptions include specific overdose warnings and education materials about DKA risk?
- Would similar overdoses of semaglutide or tirzepatide carry the same DKA risk?
Common questions
Can you overdose on GLP-1 drugs like liraglutide?
Why would someone with type 2 diabetes develop DKA from a GLP-1 drug?
Read the original research
Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
Medicine, 105(4), e46197
Citation
Xu, Hekai; Zhang, Yuqin. (2026). Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.. Medicine, 105(4), e46197. https://doi.org/10.1097/MD.0000000000046197